Market slumps on profit selling; breadth turns negative

Image
Capital Market
Last Updated : Sep 28 2021 | 12:50 PM IST
The main equity indices extended losses and hit fresh intraday low in early afternoon trade. The Nifty slipped below 17,700 mark for a brief period but soon reclaimed that level. PSU banks and metal stocks bucked weak market trend.

At 12:32 IST, the barometer index, the S&P BSE Sensex, was at 59,486.22, declining 591.66 points or 0.96%. The Nifty 50 index traded 148 points or 0.83% lower at 17,706.45.

In broader market, the S&P BSE Mid-Cap index was down 0.86% while the S&P BSE Small-Cap index fell 0.76%.

The market breadth turned negative. On the BSE, 1339 shares rose and 1771 shares fell. A total of 174 shares were unchanged.

Derivatives:

The NSE's India VIX, a gauge of market's expectation of volatility over the near term, jumped 2.42% to 18.49. The Nifty 30 September 2021 futures were trading at 17,745, at a premium of 6 points as compared with the spot at 17,739.

The Nifty option chain for 30 September 2021 expiry showed maximum Call OI of 89.4 lakh contracts at the 18,000 strike price. Maximum Put OI of 59 lakh contracts was seen at 17,000 strike price.

Buzzing Index:

The Nifty IT index slumped 2.36% to 35,185. The index has lost 5.1% in two days.

Mindtree (down 3.46%), Coforge (down 3.3%), Mphasis (down 3.29%), L&T Infotech (down 3%), HCL Tech (down 2.95%), Infosys (down 2.28%) and Wipro (down 2.23%) were top losers in IT space.

Stocks in Spotlight:

NTPC rose 4.57% to Rs 132.75 after the company won 1.9 gigawatt (GW) in the auction of CPSU Scheme-II, Tranche-III of 5 GW.

Sun Pharmaceutical Industries was down 0.12%. The drug company announced the launch of a novel formulation in cough management - Chericof 12 (dextromethorphan hydrobromide 30 mg and chlorpheniramine maleate 4 mg) in India. All cough syrups generally give relief for 6-8 hours, and hence a patient has to take it three to four times a day. Frequent dosing often leads to patient inconvenience and non-adherence to follow the regimen, which may compromise the efficacy of the medication.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 28 2021 | 12:31 PM IST

Next Story